LTR Pharma (ASX:LTP) acquired a 33% equity stake in LevOmega, which was co-founded by Levur, Green Blue Health, and the firm, with no upfront capital required, according to a Monday Australian bourse filing.
LevOmega, which is focused on developing nature-identical omega-3 products, entered into a research and development services and licensing agreement with Levur, under which it will license its proprietary advanced biotechnology platform to LevOmega.
LTR's shares jumped over 3% in recent trading on Monday.